TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TXMD
CUSIPN/A
Phone561-961-1900
Debt
Debt-to-Equity Ratio0.94
Current Ratio7.88
Quick Ratio7.79
Price-To-Earnings
Trailing P/E Ratio-14.84
Forward P/E Ratio-9.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$16.78 million
Price / Sales75.74
Cash FlowN/A
Price / CashN/A
Book Value$0.60 per share
Price / Book9.15
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-76,920,000.00
Net Margins-582.86%
Return on Equity-80.75%
Return on Assets-62.64%
Miscellaneous
Employees173
Outstanding Shares231,490,000
Market Cap$1.21 billion
TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD Inc (NASDAQ:TXMD) issued its quarterly earnings results on Monday, July, 30th. The company reported ($0.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.03. The business earned $3.80 million during the quarter, compared to analyst estimates of $4.23 million. TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. TherapeuticsMD's revenue was down 11.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.10) earnings per share. View TherapeuticsMD's Earnings History.
When is TherapeuticsMD's next earnings date?
What price target have analysts set for TXMD?
9 analysts have issued 12 month price targets for TherapeuticsMD's shares. Their predictions range from $6.00 to $27.00. On average, they anticipate TherapeuticsMD's stock price to reach $14.75 in the next year. This suggests a possible upside of 168.7% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.
What is the consensus analysts' recommendation for TherapeuticsMD?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.
Are investors shorting TherapeuticsMD?
TherapeuticsMD saw a increase in short interest in July. As of July 31st, there was short interest totalling 58,225,491 shares, an increase of 2.1% from the July 13th total of 59,455,698 shares. Based on an average daily volume of 1,977,981 shares, the short-interest ratio is currently 29.4 days. Currently, 33.5% of the shares of the stock are sold short. View TherapeuticsMD's Current Options Chain.
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX) and Akcea Therapeutics (AKCA).
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the folowing people:
- Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 47)
- Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 56)
- Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 50)
- Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 60)
- Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 52)
Has TherapeuticsMD been receiving favorable news coverage?
News stories about TXMD stock have trended positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. TherapeuticsMD earned a media and rumor sentiment score of 0.46 on Accern's scale. They also assigned media stories about the company an impact score of 50.50 out of 100, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days. View Recent Headlines for TherapeuticsMD.
Who are TherapeuticsMD's major shareholders?
TherapeuticsMD's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (14.05%), BlackRock Inc. (6.28%), FMR LLC (4.54%), Voya Investment Management LLC (1.48%), OppenheimerFunds Inc. (0.83%) and Public Employees Retirement Association of Colorado (0.49%). View Institutional Ownership Trends for TherapeuticsMD.
Which major investors are selling TherapeuticsMD stock?
TXMD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of New York Mellon Corp, Ardsley Advisory Partners, Stoneridge Investment Partners LLC, Sanders Morris Harris LLC, Bank of America Corp DE, Aperio Group LLC and Oppenheimer & Co. Inc.. View Insider Buying and Selling for TherapeuticsMD.
Which major investors are buying TherapeuticsMD stock?
TXMD stock was acquired by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, BlackRock Inc., OppenheimerFunds Inc., Voya Investment Management LLC, Raymond James & Associates, TD Asset Management Inc., State of Wisconsin Investment Board and Dupont Capital Management Corp. View Insider Buying and Selling for TherapeuticsMD.
How do I buy shares of TherapeuticsMD?
Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TherapeuticsMD's stock price today?
One share of TXMD stock can currently be purchased for approximately $5.49.
How big of a company is TherapeuticsMD?
TherapeuticsMD has a market capitalization of $1.21 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.
How can I contact TherapeuticsMD?
TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]
MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
